Citation only
via Europe PMC
Integration of cross-species multi-omics with in vivo experimental validation identifies Parkinson's disease therapeutic targets and novel risk factors within endolysosomal pathway subnetworks.
Moore J, Rao L, Garcia-Bellido S, Guo F, Botas J, Botas J.
Neurobiology of disease · 2026
Abstract
Parkinson's disease (PD), the most common neurodegenerative movement disorder, imposes a growing healthcare and socioeconomic burden worldwide. A defining hallmark of PD is the accumulation of α-synuclein (αSyn) within intracellular inclusions such as Lewy bodies and Lewy neurites. Genomic studies have identified numerous PD risk factors within the endolysosomal pathway (ELP), an essential cellular system for protein and membrane recycling. Concordantly, recurrent transcriptomic and proteomic alterations in ELP components implicate broad ELP dysfunction as a causal contributor to PD and suggest that additional, uncharacterized ELP genes may cooperate in polygenic disease mechanisms. A promising but underexplored therapeutic concept is that targeted manipulation of specific ELP genes may confer protection against αSyn-induced pathology. Distinguishing pathogenic from compensatory ELP alterations could therefore reveal strategies to enhance endogenous protective responses or counteract deleterious ones. Using an integrative multi-omic network approach, we identified high-weight subnetworks of dysregulated ELP genes that converge on known PD risk factors and potential therapeutic nodes. Experimental validation in a Drosophila model demonstrates subnetworks playing a causal role in disease progression. Notably, Endosomal Sorting Complex Required for Transport (ESCRT) and phosphatidylinositol cycle subnetworks contain multiple genes whose perturbation either worsens or mitigates PD-relevant phenotypes. Among these, manipulation of STAM1/2, INPP4A/B, and TMEM55A/B ameliorates behavioral deficits, reduces neurodegeneration, and protects dopaminergic neurons. Collectively, these findings provide new mechanistic insight into the contribution of ELP dysfunction to PD, nominate previously unrecognized therapeutic targets and risk factors, and illustrate a generalizable strategy for identifying interventions capable of reprogramming maladaptive ELP responses in neurodegeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1016/j.nbd.2026.107364
- Canonical
- link ↗
- Fetched
- 2026-07-02 MST
Cite this
APA
J, M., L, R., S, G., F, G., J, B., & J., B. (2026). Integration of cross-species multi-omics with in vivo experimental validation identifies Parkinson's disease therapeutic targets and novel risk factors within endolysosomal pathway subnetworks. <em>Neurobiology of disease</em>. https://doi.org/10.1016/j.nbd.2026.107364
Vancouver
J M, L R, S G, F G, J B, J. B. Integration of cross-species multi-omics with in vivo experimental validation identifies Parkinson's disease therapeutic targets and novel risk factors within endolysosomal pathway subnetworks. Neurobiology of disease. 2026. doi:10.1016/j.nbd.2026.107364.
BibTeX
@article{moore2026Integr,
title = {Integration of cross-species multi-omics with in vivo experimental validation identifies Parkinson's disease therapeutic targets and novel risk factors within endolysosomal pathway subnetworks.},
author = {Moore J and Rao L and Garcia-Bellido S and Guo F and Botas J and Botas J.},
journal = {Neurobiology of disease},
year = {2026},
doi = {10.1016/j.nbd.2026.107364},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Intisari Sains Medis 2025
Open access · OA
The Gut-Brain Axis: Alpha Synuclein Pathology and Its Role in Parkinson's Disease
2025
Citation only
Neuromelanin and Alpha-Synuclein in Parkinson's disease: Toward Neuroprotective Strategies
Age and Ageing 2010
Citation only
Ageing, neurodegeneration and Parkinson's disease
Molecular Neurodegeneration 2023
Open access · CC-BY
Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease
Frontiers in Aging Neuroscience 2020
Open access · CC-BY
Protein-Protein Interactions in Alpha-Synuclein Biogenesis: New Potential Targets in Parkinson’s Disease
Expert Review of Proteomics 2008
Citation only